Highlights LIDDS AB

Equities

LIDDS

SE0001958612

Market Closed - Nasdaq Stockholm Other stock markets 09:27:10 2024-05-21 am EDT			5-day change	1st Jan Change
0.1545 ^SEK	0.00%		-6.65%	+43.06%

May. 14	LIDDS AB Announces CFO Changes, Effective 1 September 2024	CI
May. 14	LIDDS AB Announces CEO Changes, Effective 1 September 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sweden's Lidds Finalizes Purchase of Noviga Research	Mar. 21	MT
LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	Mar. 20	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
LIDDS AB (OM:LIDDS) signed an agreement to acquire Noviga Research AB.	Jan. 28	CI
Lidds CFO to Take Over CEO Role; Shares Plunge	Nov. 28	MT
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc	23-07-06	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
LIDDS AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-13	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel	22-07-08	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-23	CI
LIDDS AB Next Step with Nanozolid® Formulated Docetaxel	22-02-21	CI
LIDDS AB Announces the R&D Project with Johnson & Johnson Enterprise Innovation Inc	22-01-11	CI
LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel	21-12-29	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LIDDS AB

Equities

LIDDS

SE0001958612

Highlights

Filters